Verizon Business has been selected to manage Astellas Pharma Inc’s (Astellas) network infrastructure. The deal will enable Astellas to harness tech to help reduce drug development timelines, healthcare costs and drive revenue for the Japanese pharmaceutical multinational.
Tiny smart bed sensors embedded in hospital mattresses could put an end to painful and life-threatening pressure sores, thanks to tech by the University of South Australia. UniSA scientists have designed minute optical fibre sensors, which can be attached to the upper surface of a mattress to monitor movement and record heart and respiratory rates.
Alliance Pharma (Alliance), a bioanalytical and CMC testing services firm in the pharmaceutical and biopharmaceutical industry, announced they will be opening a bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia. The 20,000-square-foot purpose-built facility supporting preclinical and clinical testing will be fully operational in November 2022.
LifeWorks, a provider of comprehensive mental health, digital and in-person total wellbeing solutions, announced an agreement with Cover-More Group to acquire Benestar, a top employee assistance program (EAP) and workplace wellbeing provider in Australia and New Zealand. Benestar is wholly owned by Cover-More, a company of Zurich Insurance Group.
Healthcare systems differ, with some providing high-quality services for free, and others causing people to quickly rack up thousands in medical bills. Does paying for healthcare mean that you are guaranteed a better service, or are free healthcare systems just as reliable? In order to delve into how simple differences between the way that healthcare systems are implemented around the world can have huge impacts on the quality of results and level of care, Radar Healthcare have carried out research in order to create their new Healthcare Mapped report.
CSL Limited is pleased to announce it has now received all necessary regulatory clearances for the acquisition of Vifor Pharma AG (Vifor) initially announced on 14 December 2021. CSL has set the settlement date of the public tender offer for Vifor for 9 August 2022. If the offer conditions that remain in effect until the settlement remain fulfilled until that date, shareholders who accepted the offer will receive the offer price for each share tendered into the offer on the settlement date, subject to the terms of the offer. CSL anticipates that it will hold more than 97% of Vifor Pharma AG shares upon the settlement of the offer and intends to have Vifor apply for the delisting of the Vifor Pharma AG Shares after the settlement.
The global pharmaceutical company Adalvo announced the acquisition of its first branded product, Onsolis® after concluding a deal with a reputable United States based specialty pharmaceutical Company, that originally owned the product. The brand is an opioid analgesic, indicated for the management of persistent breakthrough pain in cancer patients who have already received and are tolerant to opioid therapy for their underlying cancer pain.
For the 28th straight year, Cleveland Clinic is America’s No. 1 hospital for cardiology and heart surgery in U.S. News & World Report’s 2022-23 Best Hospitals rankings, while earning a Top 5 overall ranking for the 24th year in a row. It’s main campus ranks 4th in the US, placed in 13 specialties – including nine in the Top 10 and six in the Top 5 – and top ranked in Ohio.
SMOORE, a vape manufacturer, announced that is has opened China’s first non-clinical full-scale testing laboratory for Premarket Tobacco Product Applications (PMTA). A PMTA is an application that must be reviewed and approved by the Food and Drug Administration (FDA) before a new nicotine product can be legally marketed in the US. It must also provide scientific data that demonstrates a product is appropriate for the protection of public health.
Hepatitis is an inflammation of the liver and viral hepatitis is caused by one of five strains of hepatitis viruses named A to E. According to the World Health Organization, an estimated 354 million people worldwide live with hepatitis B or C, both of which are blood-borne, and which together are the most common cause of liver cirrhosis, liver cancer and viral hepatitis-related deaths. While there is a vaccine to prevent hepatitis B, there is none for hepatitis C.